Sort   by:  
 Page size 
ProteomicsGenomic determinants of protein abundance variation in colorectal cancer cell lines
Assessing the impact of genomic alterations on protein networks is fundamental in identifying the mechanisms that shape cancer heterogeneity. We have used isobaric labelling to characterize the proteomic landscapes of 50 colorectal cancer cell lines and to decipher the functional consequences of som...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
MSV000081528 | MassIVE
UnknownSafety, Feasibility, and Preliminary Efficacy of Allogeneic MSCs to Treat Advanced Femoral Head Osteonecrosis (ALOFEM): A Pilot Study in Young Onco‐Hematological Patients
Not available
S-EPMC12771626 | biostudies-literature
UnknownEfficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Not available
S-EPMC8610426 | biostudies-literature
UnknownValidation of the RIM Score-COVID in the Spanish SEMI-COVID-19 Registry.
The significant impact of COVID-19 worldwide has made it necessary to develop tools to identify patients at high risk of severe disease and death. This work aims to validate the RIM Score-COVID in the SEMI-COVID-19 Registry. The RIM Score-COVID is a simple nomogram with high predictive capacity for ...
S-EPMC9862219 | biostudies-literature
UnknownImpact of SARS-CoV-2 infection therapies on the risk of venous thromboembolism and cardiovascular events from the SEMI-COVID-19 Registry.
This study aimed to assess the impact of SARS-CoV-2 therapies on the risk of venous thromboembolism (VTE) and other cardiovascular events. A retrospective, multicenter, observational study included hospitalized patients in Spain due to acute SARS-CoV-2 infection from March 2020 to March 2022. A tota...
S-EPMC11882944 | biostudies-literature
UnknownRepurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.

Background

World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19).

Methods

We randomly assigned inpa...
S-EPMC7727327 | biostudies-literature
UnknownA multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia.
BACKGROUNDPassive immunotherapy with convalescent plasma (CP) is a potential treatment for COVID-19. Evidence from controlled clinical trials is inconclusive.METHODSWe conducted a randomized, open-label, controlled clinical trial at 27 hospitals in Spain. Patients had to be admitted for COVID-19 pne...
S-EPMC8516461 | biostudies-literature
UnknownData-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia.
Not available
S-EPMC12082131 | biostudies-literature
UnknownShaping current European mitochondrial haplogroup frequency in response to infection: the case of SARS-CoV-2 severity.
The frequency of mitochondrial DNA haplogroups (mtDNA-HG) in humans is known to be shaped by migration and repopulation. Mounting evidence indicates that mtDNA-HG are not phenotypically neutral, and selection may contribute to its distribution. Haplogroup H, the most abundant in Europe, improved sur...
S-EPMC11718132 | biostudies-literature
UnknownClonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2.
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study,...
S-EPMC10876565 | biostudies-literature
Sort   by:  
 Page size